Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- FARON.HE
- Price
- 2.17
- Stock movement up
- +0.10 (4.22%)
- Company name
- Faron Pharmaceuticals Oy
- Exchange
- (HE ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 267.10M
- Ent value
- 282.86M
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-11-11
DIVIDENDS
FARON.HE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 113.90M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | -0.32 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 6.99M |
| Net receivables | 0.00 |
| Total current assets | 9.73M |
| Goodwill | 0.00 |
| Intangible assets | 1.15M |
| Property, plant and equipment | 0.00 |
| Total assets | 11.27M |
| Accounts payable | 6.01M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 10.47M |
| Total liabilities | 22.75M |
| Shareholder's equity | -11.48M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.29 |
| Daily high | 2.37 |
| Daily low | 2.28 |
| Daily Volume | 401K |
| All-time high | 2.40 |
| 1y analyst estimate | 3.36 |
| Beta | 1.24 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 26 Feb 2026 |
Downside potential
Loading...
Downside potential data
| FARON.HE | S&P500 | |
| Current price drop from All-time high | -9.98% | -4.13% |
| Highest price drop | -6.51% | -19.00% |
| Date of highest drop | 23 Oct 2025 | 8 Apr 2025 |
| Avg drop from high | -2.51% | -2.73% |
| Avg time to new high | 4 days | 6 days |
| Max time to new high | 16 days | 89 days |
COMPANY DETAILS
Marketcap
267.10M
Marketcap category
Small-cap
Description
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. Its lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents in relapsed/refractory myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. In addition, it develops receptors involved in regulation of immune response in organ damage and bone marrow regeneration. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
Employees
32
Website
Investor relations
-
SEC filings
CEO
Country
Finland
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
The UK market has recently faced challenges, with the FTSE 100 and FTSE 250 indices experiencing declines amid weak trade data from China, highlighting global economic uncertainties. In such a landsca...
November 7, 2025
In recent times, the United Kingdom's stock market has faced headwinds, with the FTSE 100 index experiencing a downturn due to weak trade data from China and broader global economic pressures. Amid th...
November 6, 2025
This acceptance marks the fifth major medical conference this year to feature bexmarilimab in an oral session, reinforcing the drug's unique mechanism in hematologic malignancies and potential to impr...
November 4, 2025
TURKU, FI / ACCESS Newswire / November 3, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Having achieved all primary endpoints and secured FDA alignment, Faron formally concludes enrolment of th...
November 3, 2025
The UK market has recently faced challenges, with the FTSE 100 and FTSE 250 indices experiencing declines due to weak trade data from China, highlighting global economic uncertainties. In such a clima...
October 27, 2025
The United Kingdom's FTSE 100 index recently experienced a downturn, influenced by weak trade data from China, underscoring the interconnectedness of global markets and their impact on domestic indice...
October 24, 2025
TURKU, FINLAND / ACCESS Newswire / October 21, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) Faron Pharmaceuticals Ltd | Company announcement | October 21, 2025 at 16:10:00 EEST TR-1: Standard fo...
October 21, 2025
TURKU, FI / ACCESS Newswire / October 20, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinic...
October 20, 2025
The United Kingdom's stock market has recently faced challenges, with the FTSE 100 and FTSE 250 indices experiencing declines amid concerns about China's economic recovery and its impact on global tra...
October 15, 2025
In recent months, the UK market has faced challenges as the FTSE 100 index faltered amid weak trade data from China, highlighting concerns over global economic recovery and its impact on London’s blue...
October 14, 2025
Next page